Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus GP2017 for radiographic progression in active ankylosing spondylitis
2017-000679-10Phase 3Unknown
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of secukinumab and adalimumab in ankylosing spondylitis (AS) (3 arms), sponsored by Novartis. Primary endpoint: No radiographic progression at Week 104. Status: unknown.
02
Drugs
secukinumabadalimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2017-000679-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000679-10.